secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001104659-25-047013
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Q1 net loss $7.3M; SERENITY At-Home trial fully enrolled, data H2 2025
------------------------------------------------------------------------------

- Net revenue from IGALMI fell to $168K in Q1 2025 from $582K in Q1 2024.
- Net loss of $7.3M improved from $26.8M YoY on lower R&D and SG&A costs.
- Cash and equivalents $31M as of March 31, 2025.
- SERENITY At-Home pivotal Phase 3 trial fully enrolled; topline data expected H2 2025.
- TRANQUILITY In-Care Phase 3 trial for Alzheimer's agitation is advancing toward initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/0001104659-25-047013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/tm2514754d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer